The DOI matches its Crossref record.
Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies
Abstract
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness. DATA SOURCES: The MEDLINE/PubMed and Google Scholar databases were systematically searched for relevant articles published prior to October 2015. Search terms included various combinations of the following: major depressive disorder (MDD), depression, mental illness, mood disorder, antidepressant, response, remission, outcome, pharmacogenetic, pharmacogenomics, pharmacodynamics, pharmacokinetic, genetic testing, genome wide association study (GWAS), CYP450, personalized medicine, cost-effectiveness, and pharmacoeconomics. STUDY SELECTION: Of the 66 records identified from the initial search, relevant clinical studies, written in English, assessing the cost-effectiveness and/or efficacy of pharmacogenomic testing for MDD were included. DATA EXTRACTION: Each publication was critically examined for relevant data. RESULTS: Two nonrandomized, open-label, 8-week, prospective studies reported overall greater improvement in depressive symptom severity in the group of MDD subjects receiving psychiatric care guided by results of combinatorial pharmacogenomic testing (GeneSight) when compared to the unguided group. One industry-sponsored, randomized, double-blind, 10-week prospective study reported a trend for improved outcomes for the GeneSight-guided group; however, the trend did not reach statistical significance. Another industry-sponsored, randomized, double-blind, 12-week prospective study reported a 2.5-fold increase in remission rates in the CNSDose-guided group (P < .0001). One naturalistic, unblinded, industry-sponsored study showed clinical improvement when pharmacogenomics testing guided prescribing; however, this study lacked a control group. A single cost-effectiveness study concluded that single gene testing was not cost-effective. Conversely, a separate study reported that combinatorial pharmacogenomic testing is cost-effective. CONCLUSIONS: A limited number of studies have shown promise for the clinical utility of pharmacogenomic testing; however, cost-effectiveness of pharmacogenomics, as well as demonstration of improved health outcomes, is not yet supported with replicated evidence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationDepression in the Primary Care Setting
Park, L. T., & Zarate, C. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1712493 · Cited by 458
Lee, Y., Ragguett, R.-M., Mansur, R. B., Boutilier, J. J., Rosenblat, J. D., Trevizol, A., Brietzke, E., Lin, K., Pan, Z., Subramaniapillai, M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.073 · Cited by 408
Self-citationGreden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.003 · Cited by 347
Bousman, C. A., Arandjelovic, K., Mancuso, S. G., Eyre, H. A., & Dunlop, B. W. (2019) · Pharmacogenomics · doi:10.2217/pgs-2018-0142 · Cited by 198
Metadata
- Authors
- Rosenblat, J. D., Lee, Y., & McIntyre, R. S.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2017-06-28
- Volume
- 78
- Issue
- 06
- Pages
- 720-729
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2562914031
- Cited by
- 138
- References
- 0
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 16 · 2022: 7 · 2021: 22 · 2020: 15 · 2019: 24 · 2018: 23 · 2017: 15
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- pharmacogenetic testing, major depressive disorder, antidepressant response, antidepressant tolerability, cytochrome P450, personalized medicine, cost-effectiveness, depression remission, antidepressant selection, genetic testing
- MeSH terms
- Pharmacogenomic Testing, Clinical Trials as Topic, Cost-Benefit Analysis, Depressive Disorder, Major, Major Depressive Disorder, Humans, Outcome and Process Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. https://app.cochat.ai/papers/10.4088/jcp.15r10583
- The paper
- Rosenblat, J. D., Lee, Y., & McIntyre, R. S. (2017). Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.15r10583
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.